Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas(University of California, Los Angeles), Adil Daud(University of California, San Francisco), John M. Kirkwood(UPMC Hillman Cancer Center), Simone M. Goldinger(Melanoma Institute Australia), Karl D. Lewis(University of Colorado Denver), Jacob Schachter, Omid Hamid(Cedars-Sinai Medical Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Stergios J. Moschos(University of North Carolina at Chapel Hill), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Jedd D. Wolchok(Cornell University), Thomas Eigentler(University Children's Hospital Tübingen), Anna C. Pavlick(Cornell University), Ronnie Shapira‐Frommer(Sheba Medical Center), Lee D. Cranmer(University of Washington), Steven O’Day(Saint John's Health Center), Sanjiv S. Agarwala(Goethe University Frankfurt), Sunyu Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joy Lis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adriane M Zernhelt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Carmen Loquai(Johannes Gutenberg University Mainz), Matteo S. Carlino(The University of Sydney), Kim Margolin(City Of Hope National Medical Center), F. Stephen Hodi(Harvard University), Christian U. Blank(The Netherlands Cancer Institute), Reinhard Dummer(University Hospital of Zurich), April K.S. Salama(Duke University), Caroline Robert(Institut Gustave Roussy), Xiaoyun Li(Nanjing University), Wei Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), René González(University of Miami), Tara C. Gangadhar(University of Pennsylvania), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 1,571
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k